Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.
Current stock price: 8.20 pence
12-month change: down 33%
By Sophie Rose, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved
Genedrive (GDR)